Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration
Ophthalmology Retina · 2025
DOI: 10.1016/j.oret.2025.05.004 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Ophthalmology Retina, 2025. Verfasst von Nikolas J S London und 7 weiteren Autor:innen. Beteiligte Einrichtung: Retina Consultants San Diego, San Diego, California. Electronic address: london@rcsd.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Macula Lutea, Visual Acuity, Wet Macular Degeneration. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche, F. Hoffmann-La Roche.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Retina Consultants San Diego, San Diego, California. Electronic address: london@rcsd.com.
- Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore.
- Eye Clinic Zurich West, Zurich, Switzerland; University of Zurich, Zurich, Switzerland.
- Roche Products Ltd., Welwyn Garden City, UK.
- F. Hoffmann-La Roche Ltd., Basel, Switzerland.
- Genentech, Inc., South San Francisco, California.
Förderung
- Roche
- F. Hoffmann-La Roche
Zitieren
APA
London, N. J. S., Cheung, C. M. G., Michels, S., Kotecha, A., Margaron, P., Souverain, A., Willis, J. R., & Lai, T. Y. Y. (2025). Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2025.05.004
Vancouver
London NJS, Cheung CMG, Michels S, Kotecha A, Margaron P, Souverain A, et al. Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration. Ophthalmology Retina. 2025. doi:10.1016/j.oret.2025.05.004
BibTeX
@article{London2025,
author = {London, Nikolas J S and Cheung, Chui Ming Gemmy and Michels, Stephan and Kotecha, Aachal and Margaron, Philippe and Souverain, Audrey and Willis, Jeffrey R and Lai, Timothy Y Y},
title = {Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration},
journal = {Ophthalmology Retina},
year = {2025},
doi = {10.1016/j.oret.2025.05.004}
}
EUVIMED